Oby O.

About Oby O.

I am an R&D Strategy & Operations Associate Director specialized in governing global Biopharmaceutical portfolio management and Precision Oncology pipelines. I bridge the gap between bold scientific strategy and flawless operational execution by leading matrixed, cross-functional teams and managing $15M+ R&D portfolios through the R&D Lifecycle.My expertise centers on Strategic Governance and Portfolio Strategy, where I lead the Strategic Preparation of high-stakes Governance Board and Steering Committee presentations. I serve as a strategic gatekeeper, ensuring cross-functional project leads and senior stakeholders deliver data-driven, actionable insights that address executive leadership\'s critical questions. I drive the Investment Decision Frameworks that enable SVP-level investment approval.🧪 SCIENTIFIC STRATEGY & MODALITIESTherapeutic Areas: Oncology (Solid Tumors, Immuno-Oncology (IO)).High-Growth Modalities: Radioligand Therapy (RLT), Targeted Alpha Therapy (TAT), Radioconjugates, mAbs, VHH, Peptides, Small Molecules.R&D Lifecycle Leadership: Target ID to IND-Enabling, Preclinical Operations Strategy, Translational Medicine Operations, Lead Optimization, Candidate Selection, GLP Toxicology, and DMPK. STRATEGIC PROGRAM MANAGEMENT & PORTFOLIO GOVERNANCEPortfolio Strategy: Multi-Asset Prioritization, Resource Capacity Planning, Scenario Modeling, and Multi-Objective Decision Analysis (MODA).Strategic Investment: Concept-to-Investment Decision Support, Strategic Stage-Gates, Business Case Development, ROI Analysis, and SVP-Level Approval Support.Infrastructure & Growth: Strategic Capability Builds, Operational Readiness, and Infrastructure Capacity Planning.🤝 BUSINESS TRANSFORMATION & ALLIANCESGrowth & Change: Change Management Leadership, Enterprise Risk Mitigation, Post-Merger Integration (PMI), Organizational Redesign, and Executive Advisory (Office of the Chief of Staff).Alliance Management: Global CDMO Oversight, CRO Governance, Strategic Alliances, Master Services Agreements (MSA), and Statements of Work (SOW). DIGITAL TRANSFORMATION & STRATEGIC ANALYTICSPortfolio & Pipeline Visibility: Planisware, Planview, Timeline Pro, Smartsheet, SharePoint, and MS Project for enterprise-wide tracking.Business Intelligence (BI): Leveraging Executive Dashboards (Power BI, Tableau) and enterprise data (SAP, Oracle, Salesforce) to drive Resource & Budget Transparency.AI & GenAI Integration: Large Language Models (LLM), RLHF, Supervised Fine-Tuning (SFT), and Biomedical Prompt Engineering for clinical data optimization.

Experience

1. Associate Director, Scientific Project Manager R & d Strategic Operations Lead

   AstraZeneca

   Aug 2023 — Present · Gaithersburg, MD, US

   Executive Readiness & Governance: Led the strategic preparation and quality control for Steering Committee Leadership and Governance Board presentations, ensuring cross-functional project leads addressed executive-level concerns and Investment Decision Frameworks. Strategic Advisory: Functioned in a Chief of Staff capacity to drive business cases for internal lab and manufacturing expansion, ensuring alignment with SVP-level investment and Operational Excellence (OpEx). Portfolio Strategy & Lifecycle: Governed a $15M+ multi-asset portfolio (mAbs, VHH, peptides), leading Multi-Asset Prioritization and Preclinical Operations Strategy from Target ID to IND-Enabling milestones. Governance Standardization: Established the first Radioconjugate milestone guidance and standardized Pre-IND stage-gates, streamlining reviews and ensuring Enterprise Risk Mitigation across R&D, CMC, and Clinical functions. Post-Merger Integration (PMI): Led the operational integration of Fusion Pharmaceuticals, establishing a “Ways of Working” for the joint Radioligand Therapy (RLT)/Targeted Alpha Therapy (TAT) pipeline through Change Management Leadership. Investment Decision Frameworks: Developed a Multi-Objective Decision Analysis (MODA) framework to enable objective Scenario Modeling and “Go/No-Go” investment decisions based on safety and strategic fit. Cross-Functional Matrix Leadership: Chaired the global Radioconjugate Discovery Forum (200+ participants), leading matrixed teams across Discovery, CMC, Clinical, and Regulatory to accelerate Change Management. Resource & Budget Management: Directed external R&D spend and Resource Capacity Planning (FTE) using Coupa and SAP, achieving >10% annual savings through optimized vendor allocation. Strategic Analytics: Leveraged Planisware, Smartsheet, and advanced Excel to develop executive-level data reporting/dashboards, providing the Oncology Leadership Team with real-time visibility into GLP Tox and Efficacy data.

Education

• The Johns Hopkins University - Carey Business School

  Master of Business Administration (M.B.A.)

  2015 — 2020

• The Johns Hopkins University

  Master of Science - MS, Biotechnology

  2015 — 2020

• St. Mary's College of Maryland

  Bachelor or Arts, Biology